The gold industry standard for risk and cost of drug and vaccine development revisited
Vacceleron, Utrecht, The Netherlands. Vaccine
(Impact Factor: 3.62).
06/2011; 29(35):5846-9. DOI: 10.1016/j.vaccine.2011.06.051
Gold dimensions of pharmaceutical drug development indicate that it takes on average 11.9 years, with an investment around US$ 0.8 Billion, to launch one product on the market. Furthermore, approximately 22% of the drug candidates successfully complete clinical testing. These universally acknowledged proportions largely originate from one single, much cited publication; Dimasi et al. . However an additional six articles describing new chemical entities (NCE) development were identified, which contain little, if any, information on vaccines. Published cumulative success rates range from 7% to 78% and investments calculations span US$ 0.8 to 1.7 Billion. Obviously this disserves further clarification?
Available from: Esther S Pronker
- "observed that resources consumed during R&D do not result in the anticipated number of product launches . One aspect of this phenomenon is the success rate: the probability a candidate will successfully transition through the value chain phases . When taking pre-clinical development as a starting point, approximately 6% of the vaccine candidates reach regulatory approval (unpublished work). 2 By comparison, inter-pandemic influenza vaccines are considered lucrative, attaining an estimated 10% success rate (unpublished work). "
[Show abstract] [Hide abstract]
ABSTRACT: As infectious diseases cause approximately 25% of the annual global mortality, vaccines are found to be a time proven and promising response to infectious disease need. However, like for pharmaceutical small molecules, vaccine development is lengthy, risky and resource demanding. Faced with an attrition rate estimated around 80%, key opinion leaders were interviewed with the question: is there a recipe for success?
Vaccine 10/2012; 30(51). DOI:10.1016/j.vaccine.2012.09.071 · 3.62 Impact Factor
Journal of cardiothoracic and vascular anesthesia 04/2012; 26(4):711-20. DOI:10.1053/j.jvca.2012.02.012 · 1.46 Impact Factor
Available from: Andrew Dellinger
01/2013; 01(S7). DOI:10.4172/2155-6180.S7-e001
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.